Inhibitor Therap Financials
This page shows Inhibitor Therap (INTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Inhibitor Therap passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Inhibitor Therap generates $0.97 in operating cash flow (-$3.2M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Inhibitor Therap reported -$3.3M in net income in fiscal year 2024. This represents a decrease of 10.3% from the prior year.
Inhibitor Therap earned $-0.02 per diluted share (EPS) in fiscal year 2024. This represents an increase of 0.0% from the prior year.
Inhibitor Therap held $5.6M in cash against $0 in long-term debt as of fiscal year 2024.
Inhibitor Therap had 172M shares outstanding in fiscal year 2024. This represents an increase of 0.2% from the prior year.
Inhibitor Therap invested $1.7M in research and development in fiscal year 2024. This represents an increase of 21.8% from the prior year.
INTI Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $378K+2.2% | $370K | N/A | $261K | N/A | $0-100.0% | $6K | $0 |
| SG&A Expenses | $363K-18.1% | $444K | N/A | $499K | N/A | $70K+8.2% | $65K-30.9% | $94K |
| Operating Income | -$741K+8.9% | -$813K | N/A | -$760K | N/A | -$70K+1.2% | -$71K+24.3% | -$94K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $8K+13.9% | $7K+25.0% | $5K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$712K+2.6% | -$731K | N/A | -$665K | N/A | -$78K-0.2% | -$78K+21.6% | -$99K |
| EPS (Diluted) | $0.00 | $0.00 | N/A | $0.00 | N/A | $0.00 | $0.00 | N/A |
INTI Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.1M-44.9% | $5.7M-36.4% | $8.9M-6.9% | $9.6M-19.8% | $12.0M+18872.9% | $63K+63.9% | $39K-37.0% | $61K |
| Current Assets | $3.1M-46.2% | $5.7M-36.4% | $8.9M-6.9% | $9.6M-19.8% | $12.0M+18872.9% | $63K+63.9% | $39K-37.0% | $61K |
| Cash & Equivalents | $3.0M-46.9% | $5.6M-36.6% | $8.8M-7.3% | $9.5M-20.2% | $12.0M+22424.8% | $53K+112.7% | $25K-31.5% | $36K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.1M-15.6% | $3.7M+1.2% | $3.7M+16.1% | $3.2M-14.2% | $3.7M-10.0% | $4.1M+3.9% | $3.9M+2.7% | $3.8M |
| Current Liabilities | $88K-87.7% | $710K+6.7% | $665K+325.2% | $156K-77.0% | $679K-37.6% | $1.1M+16.3% | $935K+12.6% | $830K |
| Long-Term Debt | $44K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3K-99.8% | $2.0M-62.4% | $5.3M-18.1% | $6.5M-22.2% | $8.3M+306.1% | -$4.0M-3.3% | -$3.9M-3.4% | -$3.8M |
| Retained Earnings | -$54.1M-3.8% | -$52.1M-6.8% | -$48.8M-2.5% | -$47.6M-4.1% | -$45.8M+21.2% | -$58.1M-0.2% | -$57.9M-0.2% | -$57.8M |
INTI Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$761K+1.3% | -$771K-10.6% | -$698K-24.0% | -$563K-104.7% | $11.9M+23030.9% | -$52K+15.6% | -$61K-39.2% | -$44K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | $0 | $0 | $0-100.0% | $80K+60.0% | $50K0.0% | $50K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
INTI Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -22.7%-11.4pp | -11.3% | N/A | -6.9% | N/A | -123.1%+78.3pp | -201.4%-39.6pp | -161.8% |
| Current Ratio | 35.00+27.0 | 8.03-5.4 | 13.45-48.0 | 61.41+43.8 | 17.64+17.6 | 0.06+0.0 | 0.04-0.0 | 0.07 |
| Debt-to-Equity | 12.79+10.9 | 1.87+1.2 | 0.69+0.2 | 0.49+0.0 | 0.44+1.5 | -1.020.0 | -1.010.0 | -1.02 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Inhibitor Therap profitable?
No, Inhibitor Therap (INTI) reported a net income of -$3.3M in fiscal year 2024.
What is Inhibitor Therap's earnings per share (EPS)?
Inhibitor Therap (INTI) reported diluted earnings per share of $-0.02 for fiscal year 2024. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Inhibitor Therap's operating cash flow?
Inhibitor Therap (INTI) generated -$3.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Inhibitor Therap's total assets?
Inhibitor Therap (INTI) had $5.7M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Inhibitor Therap spend on research and development?
Inhibitor Therap (INTI) invested $1.7M in research and development during fiscal year 2024.
How many shares does Inhibitor Therap have outstanding?
Inhibitor Therap (INTI) had 172M shares outstanding as of fiscal year 2024.
What is Inhibitor Therap's current ratio?
Inhibitor Therap (INTI) had a current ratio of 8.03 as of fiscal year 2024, which is generally considered healthy.
What is Inhibitor Therap's debt-to-equity ratio?
Inhibitor Therap (INTI) had a debt-to-equity ratio of 1.87 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Inhibitor Therap's return on assets (ROA)?
Inhibitor Therap (INTI) had a return on assets of -58.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Inhibitor Therap's cash runway?
Based on fiscal year 2024 data, Inhibitor Therap (INTI) had $5.6M in cash against an annual operating cash burn of $3.2M. This gives an estimated cash runway of approximately 21 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Inhibitor Therap's Piotroski F-Score?
Inhibitor Therap (INTI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inhibitor Therap's earnings high quality?
Inhibitor Therap (INTI) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.